Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Zhichao Jiang, Aiping Zhou, Lin Yang et al.|Journal of Clinical Oncology|2024Cited by 1